Cutting edge: functional characterization of the effect of the C3H/HeJ defect in mice that lack an Lpsn gene: in vivo evidence for a dominant negative mutation
about
Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signalingFilamentation by Escherichia coli subverts innate defenses during urinary tract infectionGenetic control of the innate immune responseMacrophage: SHIP of ImmunityInternational Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and diseaseLeishmania chagasi T-cell antigens identified through a double library screenMale CD81 knockout genotype disrupts Mendelian distribution of offspring.Purified lipopolysaccharide from Francisella tularensis live vaccine strain (LVS) induces protective immunity against LVS infection that requires B cells and gamma interferon.Upregulation of toll-like receptor 2 gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is involved in NF-kappa b activation.Murine retroviruses activate B cells via interaction with toll-like receptor 4Toll-like receptors: molecular mechanisms of the mammalian immune response.Host immune response to Salmonella enterica serovar Typhimurium infection in mice derived from wild strainsMD-2, a novel accessory molecule, is involved in species-specific actions of Salmonella lipid A.The polysaccharide portion plays an indispensable role in Salmonella lipopolysaccharide-induced activation of NF-kappaB through human toll-like receptor 4.Lipopolysaccharide-mimetic activities of a Toll-like receptor 2-stimulatory substance(s) in enterobacterial lipopolysaccharide preparations.Dominant negative down-regulation of endotoxin-induced tumor necrosis factor alpha production by Lps(d)/RanTLR4 mutation and HSP60-induced cell death in adult mouse cardiac myocytes.Role of toll-like receptor 4 in acute neutrophilic lung inflammation induced by intratracheal bacterial products in mice.M1 and M2 macrophages: the chicken and the egg of immunityDistinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections.Toll-like receptor polymorphisms, inflammatory and infectious diseases, allergies, and cancer.Role of TLR-4 in liver macrophage and endothelial cell responsiveness during acute endotoxemiaTherapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer.Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture.Differential expression of caveolin-1 in lipopolysaccharide-activated murine macrophages.Structural Modifications of Bacterial Lipopolysaccharide that Facilitate Gram-Negative Bacteria Evasion of Host Innate Immunity.The Lyme disease spirochete Borrelia burgdorferi utilizes multiple ligands, including RNA, for interferon regulatory factor 3-dependent induction of type I interferon-responsive genesRoles for thrombin and fibrin(ogen) in cytokine/chemokine production and macrophage adhesion in vivo.Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice.Kaposi sarcoma-associated herpesvirus latency locus renders B cells hyperresponsive to secondary infections
P2860
Q24671928-CFE37171-6454-4D8E-A706-86488607BEF5Q24675633-E54B8D2E-970F-4CE4-BF09-B44BAB31E282Q24676540-D3618D82-1DDE-45CE-AB61-DC1FE9979CBCQ24800607-259C6512-4C20-40BB-BCCB-D392C629D836Q27027100-A15F7EE1-AA9C-4E4C-A945-0C0A65C4E34FQ28081406-89D75B59-62A7-4ECA-B875-BBD100ED5403Q33258365-F462A5C0-D746-4990-990E-CEE610A8F4E6Q33932918-35839371-709B-426F-B1D3-0E45001142C3Q34003871-CB94FDBB-0095-455B-927E-E6BE7436B74DQ34007111-64106CF8-42FB-4719-B4D7-E52E5148503BQ34013073-D2869857-EADF-4FDE-93D6-BF187B2ACA1EQ34049969-23FA1C8E-48E0-4A49-9FD3-E43A96B7FA5AQ34120673-0905A3AF-17D5-4F88-AB7C-DD9DBEDE1AFBQ34126101-D6A7711A-950A-4F22-9547-7CD2AB903B38Q34182158-82544484-4058-4CE0-8585-017CB71B9861Q35012008-B4D7C496-C616-4D88-B4B2-B6F9349D52ECQ35082639-B4BED06F-C813-4C04-9D80-1A9F47705EA4Q35529067-4CD7A659-0349-4C2A-BBD1-459C2209FC73Q35557356-BAA64179-6086-4AF0-A615-9A931B9B8997Q35600855-8B0891AF-A37B-438B-9696-7990CEB1C1DCQ36371624-7E9462F5-4EA0-42E3-B078-B2E444CAB575Q37139589-FAD874A3-0FB2-4AAA-95F7-8EAC3EF54046Q37254135-7A7A7451-88BC-43E8-8D04-AD3D69CDDAA0Q37497786-46BAFA59-E299-4F6E-A1D5-9108AD60FE84Q39519164-888EF9C4-B57C-4069-AD75-160A505CA892Q39537947-C216E32F-3C67-4A18-8C6D-A1916FF82763Q40995016-A59B115A-B63E-44C4-81E9-47D444D1620FQ41864763-5B61EEB3-8F5B-491F-A220-429AE28F80ABQ42044945-B532FDAA-65DF-4237-80F5-9108B7BE8028Q47159679-29D3B208-525C-4AFA-B408-47B04238F013Q56345322-544C9696-5946-462F-A731-B0586331EE7E
P2860
Cutting edge: functional characterization of the effect of the C3H/HeJ defect in mice that lack an Lpsn gene: in vivo evidence for a dominant negative mutation
description
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1999
@ast
im Mai 1999 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1999/05/15)
@sk
vědecký článek publikovaný v roce 1999
@cs
wetenschappelijk artikel (gepubliceerd op 1999/05/15)
@nl
наукова стаття, опублікована в травні 1999
@uk
مقالة علمية (نشرت في 15-5-1999)
@ar
name
Cutting edge: functional chara ...... r a dominant negative mutation
@ast
Cutting edge: functional chara ...... r a dominant negative mutation
@en
Cutting edge: functional chara ...... r a dominant negative mutation
@nl
type
label
Cutting edge: functional chara ...... r a dominant negative mutation
@ast
Cutting edge: functional chara ...... r a dominant negative mutation
@en
Cutting edge: functional chara ...... r a dominant negative mutation
@nl
prefLabel
Cutting edge: functional chara ...... r a dominant negative mutation
@ast
Cutting edge: functional chara ...... r a dominant negative mutation
@en
Cutting edge: functional chara ...... r a dominant negative mutation
@nl
P2093
P1476
Cutting edge: functional chara ...... r a dominant negative mutation
@en
P2093
A. Medvedev
D. Johnson
L. Larivière
P. Y. Perera
S. N. Vogel
S. T. Qureshi
P304
P407
P577
1999-05-15T00:00:00Z